Analysis of clinical characteristics and prognostic factors for angioimmunoblastic T-cell lymphoma

详细信息    查看全文

• 作者：Yoshihiro Kameoka ; Naoto Takahashi ; Shigeki Itou…
• 关键词：AITL ; IPI ; PIT ; Prognostic factor
• 刊名：International Journal of Hematology
• 出版年：2015
• 出版时间：June 2015
• 年：2015
• 卷：101
• 期：6
• 页码：536-542
• 全文大小：432 KB
• 参考文献：1.Mourad N, Mounier N, Brière J, Raffoux E, Delmer A, Feller A, et al. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d’Etude des Lymphomes de l’Adulte (GELA) trials. Blood. 2008;111:4463-0.PubMed Central PubMed View Article
  2.Rüdiger T, Weisenburger DD, Anderson JR, Armitage JO, Diebold J, MacLennan KA, et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin’s Lymphoma Classification Project. Ann Oncol. 2002;13:140-.PubMed View Article
  3.de Leval L, Rickman DS, Thielen C, Reynies Ad, Huang YL, Delsol G, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood. 2007;109:4952-3.PubMed View Article
  4.Attygalle A, Al-Jehani R, Diss TC, Munson P, Liu H, Du MQ, et al. Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10. Blood. 2002;99:627-3.PubMed View Article
  5.Dupuis J, Boye K, Martin N, Copie-Bergman C, Plonquet A, Fabiani B, et al. Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T cells. Am J Surg Pathol. 2006;30:490-.PubMed View Article
  6.Dorfman DM, Brown JA, Shahsafaei A, Freeman GJ. Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma. Am J Surg Pathol. 2006;30:802-0.PubMed Central PubMed View Article
  7.Federico M, Rudiger T, Bellei M, Nathwani BN, Luminari S, Coiffier B, et al. Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma:analysis of the international peripheral T-cell lymphoma project. J Clin Oncol. 2013;31:240-.PubMed Central PubMed View Article
  8.Frizzera G, Moran EM, Rappaport H. Angio-immunoblastic lymphadenopathy with dysproteinaemia. Lancet. 1974;1:1070-.PubMed View Article
  9.Siegert W, Agthe A, Griesser H, Schwerdtfeger R, Brittinger G, Engelhard M, et al. Treatment of angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma using prednisone with or without the COPBLAM/IMVP-16 regimen. A multicenter study. Kiel Lymphoma Study Group. Ann Intern Med. 1992;117:364-0.PubMed View Article
  10.Siegert W, Nerl C, Meuthen I, Zahn T, Brack N, Lennert K, et al. Recombinant human interferon-alpha in the treatment of angioimmunoblastic lymphadenopathy:results in 12 patients. Leukemia. 1991;5:892-.PubMed
  11.Advani R, Warnke R, Sikic BI, Horning S. Treatment of angioimmunoblastic T-cell lymphoma with cyclosporine. Ann Oncol. 1997;8:601-.PubMed View Article
  12.Pautier P, Devidas A, Delmer A, Dombret H, Sutton L, Zini JM, et al. Angioimmunoblastic-like T-cell non Hodgkin’s lymphoma: outcome after chemotherapy in 33 patients and review of the literature. Leuk Lymphoma. 1999;32:545-2.PubMed
  13.Siegert W, Nerl C, Agthe A, Engelhard M, Brittinger G, Tiemann M, et al. Angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma:prognostic impact of clinical observations and laboratory findings at presentation. The Kiel Lymphoma Study Group. Ann Oncol. 1995;6:659-4.PubMed
  14.A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987-4.
  15.Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103:2474-.PubMed View Article
  16.Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.PubMed
  17.Cheson BD, Pfistner B, Juweid ME, Shipp MA, Fisher RI, Connors JM, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579-6.PubMed View Article
  18.Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-1.View Article
  19.Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-0.PubMed
  20.Tokunaga T, Shimada K, Yamamoto K, Chihara D, Ichihashi T, Oshima R, et al. Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in Japan. Blood. 2012;119:2837-3.PubMed View Article
  21.Watanabe T, Kinoshita T, Itoh K, Yoshimura K, Ogura M, Kagami Y, et al. Pretreatment total serum protein is a significant prognostic factor for the outcome of patients with peripheral T/natural killer-cell lymphomas. Leuk Lymphoma. 2010;51:813-1.PubMed View Article
  22.Lee SS, Rüdiger T, Odenwald T, Roth S, Starostik P, Müller-Hermelink HK. Angioimmunoblastic T cell
• 作者单位：Yoshihiro Kameoka (1) (11)
  Naoto Takahashi (1)
  Shigeki Itou (2)
  Masaaki Kume (3)
  Hideyoshi Noji (4)
  Yuichi Kato (5)
  Yoshikazu Ichikawa (6)
  Osamu Sasaki (7)
  Mutsuhito Motegi (8)
  Atsushi Ishiguro (9)
  Hiroyuki Tagawa (1)
  Kenichi Ishizawa (10)
  Yoji Ishida (2)
  Ryo Ichinohasama (10)
  Hideo Harigae (10)
  Kenichi Sawada (1)
  
  1. Department of Hematology, Akita University, Akita, Japan
  11. Division of Hematology, Nephrology, and Rheumatology, Akita University School of Medicine, 44-2 Hasunuma Hiroomote, Akita City, Akita, 010-0041, Japan
  2. Department of Hematology and Oncology, Iwate Medical University, Morioka, Japan
  3. Department of Internal Medicine, Hiraka General Hospital, Yokote, Japan
  4. Department of Cardiology and Hematology, Fukushima Medical University, Fukushima, Japan
  5. Department of Hematology, Yamagata University, Yamagata, Japan
  6. Department of Internal Medicine, Akita City Hospital, Akita, Japan
  7. Department of Hematology, Miyagi Cancer Center, Natori, Japan
  8. Department of Internal Medicine, Senboku Hospital, Daisen, Japan
  9. Department of Oncology, Hirosaki University, Hirosaki, Japan
  10. Department of Hematopathology, Tohoku University, Sendai, Japan
  
• 刊物主题：Hematology; Oncology;
• 出版者：Springer Japan
• ISSN：1865-3774

文摘

Angioimmunoblastic T-cell lymphoma (AITL) is a distinct peripheral T-cell lymphoma entity exhibiting peculiar clinical features and poor prognosis. Its clinical characteristics and prognostic factors are not well established. To clarify the clinical characteristics and prognostic features of AITL, we conducted a multicenter, retrospective study. Fifty-six patients were enrolled. The median patient age was 68?years. Immunohistochemical examinations of tumor cells showed positivity for CD10 and T-cell markers, and chromosomal examination detected several types of abnormalities. More than 80?% of patients show advanced disease at diagnosis and poor prognostic scores. A high proportion of patients showed accompanying B symptoms, splenomegaly, and hepatomegaly at diagnosis. The 5-year overall survival (OS) rate was 48?% and progression-free survival was 25?%. Univariate analysis revealed higher age, fever, poor performance status, anemia, and low albumin level to be poor prognostic factors for OS. In addition to these factors, both IPI and PIT were also predictive of OS. Multivariate analysis indicated only a low level of serum albumin to be a significant prognostic factor for OS. Serum albumin may be one of the important prognostic factors for AITL. Further investigation is needed to confirm these results.